The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
FUROSEMIDE-REACH (Reach Pharmaceuticals Pty Ltd)
Product name
FUROSEMIDE-REACH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
118 (255 working days)
Active ingredients
furosemide
Registration type
New generic medicine
Indication
Oedema
FUROSEMIDE-REACH is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. FUROSEMIDE-REACH is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.
FUROSEMIDE-REACH is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, FUROSEMIDE-REACH is indicated by the intravenous route. Parenteral use should be replaced with oral therapy as soon as practical.